(Total Views: 165)
Posted On: 02/09/2017 10:10:27 AM
Post# of 72447
"Cellceutix believes that this clinical trial, using IV dosing, will directly inform how Kevetrin modulates the p53 signaling pathway—one of the key questions asked by pharmaceutical companies under Confidential Disclosure Agreement (CDA)."
(2)
(0)
If you try to defend yourself against lies of the board moderators your post will be deleted. Just like the board they claim to be better than!!! Watch who you trust especially the "long term investors" that support the real attackers!
